Abstract

Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?
Robert J Fontana
Gastroenterology | VOL. 130
Robert J FontanaRobert J Fontana
01 Apr 2006
Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients
Vincenzo Guadagnino ... Luca Messerini
Gastroenterology | VOL. 130
Vincenzo Guadagnino, et. al.Vincenzo Guadagnino ... Luca Messerini
01 Apr 2006
Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
Thomas Berg ... Miriam Huber
Gastroenterology | VOL. 129
Thomas Berg, et. al.Thomas Berg ... Miriam Huber
01 Aug 2005
Virological Response in Patients with??Hepatitis C Virus Genotype 1b and??a??High Viral Load
Gotaro Yamada ... Takahiro Sakai
Clinical Drug Investigation | VOL. 28
Gotaro Yamada, et. al.Gotaro Yamada ... Takahiro Sakai
01 Jan 2008
View more papers

More From: Clinical and Molecular Hepatology

Paper Title
Journal
Date
Author
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction.
Mehrangiz Dezhbord ... Kyun-Hwan Kim
Clinical and molecular hepatology | VOL. -
Mehrangiz Dezhbord, et. al.Mehrangiz Dezhbord ... Kyun-Hwan Kim
14 May 2024
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure.
Hae Lim Lee ... Jeong Won Jang
Clinical and molecular hepatology | VOL. -
Hae Lim Lee, et. al.Hae Lim Lee ... Jeong Won Jang
14 May 2024
Unveiling Etiology-Specific Blood Biomarkers in Hepatocellular Carcinoma: A Gateway to Personalized Medicine.
Joseph C Ahn ... Ju Dong Yang
Clinical and molecular hepatology | VOL. -
Joseph C Ahn, et. al.Joseph C Ahn ... Ju Dong Yang
14 May 2024
Macrophage ATG16L1 expression suppresses MASH progression by promoting lipophagy.
Qi Wang ... Ling Lu
Clinical and molecular hepatology | VOL. -
Qi Wang, et. al.Qi Wang ... Ling Lu
10 May 2024
View more papers